US 11,867,689 B2
Engineered renal tissues, arrays thereof, and methods of making the same
Deborah Lynn Greene Nguyen, San Diego, CA (US); Shelby Marie King, San Diego, CA (US); and Sharon C. Presnell, San Diego, CA (US)
Assigned to ORGANOVO, INC., San Diego, CA (US)
Filed by Organovo, Inc., San Diego, CA (US)
Filed on Mar. 25, 2021, as Appl. No. 17/212,480.
Application 17/212,480 is a division of application No. 16/154,447, filed on Oct. 8, 2018, granted, now 10,962,526.
Application 16/154,447 is a continuation of application No. 15/259,264, filed on Sep. 8, 2016, granted, now 10,094,821, issued on Oct. 9, 2018.
Application 15/259,264 is a continuation of application No. 14/876,659, filed on Oct. 6, 2015, granted, now 9,481,868, issued on Nov. 1, 2018.
Claims priority of provisional application 62/140,285, filed on Mar. 30, 2015.
Claims priority of provisional application 62/060,416, filed on Oct. 6, 2014.
Prior Publication US 2021/0208132 A1, Jul. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/50 (2006.01); C12N 5/071 (2010.01)
CPC G01N 33/5014 (2013.01) [C12N 5/0684 (2013.01); C12N 5/0697 (2013.01); G01N 33/5044 (2013.01); C12N 2502/1323 (2013.01); C12N 2502/256 (2013.01); C12N 2502/28 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01)] 20 Claims
 
1. A method of assessing the renal toxicity of a therapeutic agent, the method comprising:
a. contacting the therapeutic agent with a three-dimensional, engineered, bioprinted, biological renal tubule model comprising:
i. a layer of renal interstitial tissue, the renal interstitial tissue comprising renal fibroblasts and endothelial cells, and
ii. a layer of renal epithelial tissue, the renal epithelial tissue comprising renal tubular epithelial cells from a subject with a disease that affects kidney function,
wherein the fibroblasts and endothelial cells are present in a ratio of fibroblasts to endothelial cells at which the renal tubule model is planar six days post- printing;
b. measuring viability or functionality of the renal tubular epithelial cells; and
c. assessing the renal toxicity of the therapeutic agent based on the measured viability or functionality of the renal tubular epithelial cells.